SCHEMBL1126873

SCHEMBL1126873

CCc1c(N)cccc1C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.55
G6PD P11413 1/20 0.46
CASP7 P55210 1/20 0.46
CASP6 P55212 1/20 0.46
ALDH1A1 P00352 6/20 0.44
HSD17B10 Q99714 5/20 0.44
KDM4E B2RXH2 3/20 0.44
NPC1 O15118 1/20 0.44
CASP3 P42574 1/20 0.44
RAB9A P51151 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
CLCN2 P51788 1/20 0.44
GABRP O00591 2/20 0.43
GABRD O14764 2/20 0.43
GABRA1 P14867 2/20 0.43
GABRB1 P18505 2/20 0.43
GABRG2 P18507 2/20 0.43
GABRB3 P28472 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL502321 0.92 MMP2 (0.47) MMP2G6PDCASP7CASP6ALDH1A1
SCHEMBL1673477 0.86 ALDH1A1 (0.46) MMP2ALDH1A1HSD17B10KDM4EALOX15
SCHEMBL1355391 0.86 ALDH1A1 (0.52) MMP2G6PDCASP7CASP6ALDH1A1
SCHEMBL5135888 0.85 MMP2 (0.52) MMP2G6PDCASP7CASP6ALDH1A1
SCHEMBL3806401 0.85 ALDH1A1 (0.44) MMP2ALDH1A1HSD17B10KDM4ECDC25B
SCHEMBL3622851 0.85 PARP1 (0.46) MMP2ALDH1A1HSD17B10KDM4EHPGD
Hydrochloric Acid SCHEMBL28057982 0.83 PARP1 (0.45) MMP2ALDH1A1HSD17B10KDM4ECDC25B
SCHEMBL282356 0.83 ALDH1A1 (0.43) MMP2ALDH1A1HSD17B10KDM4ECDC25B
SCHEMBL8743511 0.82 GABRP (0.49) MMP2CASP6ALDH1A1HSD17B10KDM4E
SCHEMBL8479420 0.82 MMP2 (0.57) MMP2G6PDCASP7CASP6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018188785-A1 COMPOUND, COMPOUND FOR USE IN THE TREATMENT OF A PATHOLOGICAL CONDITION, A PHARMACEUTICAL COMPOSITION AND A METHOD FOR PREPARING SAID COMPOUND Technische Universität München (DE) 2018-10-18 WO claimed
EP-3388430-A1 COMPOUND, COMPOUND FOR USE IN THE TREATMENT OF A PATHOLOGICAL CONDITION, A PHARMACEUTICAL COMPOSITION AND A METHOD FOR PREPARING SAID COMPOUND Technische Universität München (DE) 2018-10-17 EP claimed
EP-3229801-A1 FACTOR IXA INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-10-18 EP claimed
WO-2016094260-A1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-06-16 WO claimed
JP-2005533066-A 2005-11-04 JP claimed
EP-1527070-A1 AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2005-05-04 EP claimed
WO-2005030709-A1 NOVEL SULFONE AMIDE DERIVATIVES CAPABLE OF INHIBITING BACE LG LIFE SCIENCES LTD. (KR) 2005-04-07 WO claimed
WO-2003106455-A1 AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-12-24 WO claimed
EP-0254009-B1 A PROCESS FOR PURIFYING DINITROANILINE HERBICIDES AGAN CHEMICAL MANUFACTURERS LTD. (IL) 1991-04-17 EP claimed
CN-119053211-A Preparation method and application of ultra-small grain full-coverage infrared perovskite film 河南省科学院物理研究所 2024-11-29 CN disclosed
US-12054491-B2 Substituted benzo[f]imidazo[1,5-a][1,4]diazepines as GABA(a) receptor modulators UWM RESEARCH FOUNDATION, INC. (US) 2024-08-06 US disclosed
US-20240226165-A1 Methods of Producing Improved Immune Cell Populations Prescient Therapeutics Ltd (AU) 2024-07-11 US disclosed
WO-2024013308-A2 METHOD OF REDUCING NITRO COMPOUNDS THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) 2024-01-18 WO disclosed
EP-3450506-B1 THERMOPLASTIC ELASTOMER COMPOSITION, PRODUCTION METHOD THEREFOR, AND ELASTOMER MOLDED BODY JXTG NIPPON OIL & ENERGY CORP (JP) 2023-10-18 EP disclosed
US-5530028-A CONTROLS INSECTS OF THE ORDER LEPIDOPTERA ROHM AND HAAS COMPANY (US) 1996-06-25 US disclosed
EP-0491943-A4 TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS RORER INT HOLDINGS (US) 1996-02-14 EP disclosed
EP-0602794-A2 Insecticidal N'-substituted-N, N'-diacylhydrazines ROHM AND HAAS COMPANY (US) 1994-06-22 EP disclosed
US-5162336-A Disorders of gastrointestinal, central nervous and appetite regulatory systems RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1992-11-10 US disclosed
EP-0491943-A1 TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-07-01 EP disclosed
WO-1992000295-A1 TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12054491-B2 Substituted benzo[f]imidazo[1,5-a][1,4]diazepines as GABA(a) receptor modulators GABRA5, GABRA4, GABRA1 MMP2 3881/4885G6PD 4270/4885CASP7 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.